Cagrilintide in Thailand has been close to impossible to source until now. Most peptide suppliers in the country carry the incretin peptides, retatrutide, tirzepatide and semaglutide, and stop there. Cagrilintide works on a completely different pathway, the amylin system, which is exactly why researchers want it alongside those compounds rather than instead of them. Reta Bangkok stocks it as a retatrutide and cagrilintide blend, and as far as we can tell we are currently the only supplier in Thailand that does. This article explains what cagrilintide is, what the published trials show, and why the combination with retatrutide is drawing so much attention.

Reta Bangkok supplies every product strictly for laboratory research. Nothing on this page is medical advice. The clinical figures below come from published trials and appear here for reference only.

What cagrilintide is

Cagrilintide, development code NNC0174-0833, is a synthetic analogue of human amylin. Native amylin breaks down within minutes and tends to clump into fibrils, which makes it useless as a research compound. Novo Nordisk’s chemists modified the sequence to stop the clumping and attached a fatty acid chain so it binds to albumin in the blood. As a result, cagrilintide has a half life of roughly a week, which puts it in the same once weekly category as retatrutide and tirzepatide.

Technically it is a dual amylin and calcitonin receptor agonist, often shortened to DACRA. That matters because amylin receptors are built from a calcitonin receptor core plus a modifying protein, so a compound that hits both gets a fuller amylin like response than one that hits the amylin receptor alone.

Why amylin is a different pathway

Retatrutide, tirzepatide and semaglutide all work through the incretin system: GLP-1, GIP and in retatrutide’s case glucagon. They act largely in the gut and in the hypothalamus. Amylin, by contrast, signals through the area postrema in the brainstem, a region the incretin peptides reach only weakly. Both pathways reduce appetite and slow gastric emptying, but they do it through different receptors in different places. For a researcher, that is the whole point. Two compounds acting on the same receptor compete with each other. Two compounds acting on separate pathways can add up.

	Cagrilintide	Retatrutide
Receptor targets	Amylin, calcitonin	GLP-1, GIP, glucagon
Hormone system	Amylin	Incretin
Main signalling site	Brainstem (area postrema)	Gut and hypothalamus
Approximate half life	7 to 8 days	6 days
Developer	Novo Nordisk	Eli Lilly
Status	Phase 3 (with semaglutide), not approved	Phase 3, not approved

What the published trials show

The figures below come from peer reviewed trials. We include them so researchers can see how cagrilintide has performed in the literature, not as a recommendation of any kind.

Cagrilintide alone: Phase 2

The Phase 2 dose finding trial (The Lancet, 2021) followed 706 adults with overweight or obesity for 26 weeks. At the highest weekly amount studied, participants lost a mean of 10.8 percent of their body weight, compared with 3.0 percent on placebo. Notably, that beat the active comparator in the same trial, liraglutide, which produced 9.0 percent. For a compound acting on a single new pathway over only 26 weeks, that was a strong result.

Cagrilintide with semaglutide: REDEFINE 1

REDEFINE 1 (New England Journal of Medicine, 2025) is the Phase 3 trial of CagriSema, a fixed combination of cagrilintide and semaglutide. It followed 3,417 adults for 68 weeks. Participants on the combination lost a mean of 22.7 percent of their body weight, compared with 2.3 percent on placebo. In the same trial, semaglutide alone produced 16.1 percent and cagrilintide alone 11.8 percent. In other words, adding the amylin analogue to the GLP-1 agonist added several percentage points that neither compound reached by itself. That additive effect is the reason the amylin pathway now attracts so much research attention.

Cagrilintide with retatrutide: no trial yet

Nobody has published a clinical trial combining cagrilintide with retatrutide, and there is no commercial product in development that pairs them. The logic researchers apply is simple, though. Retatrutide is the most potent incretin agonist with published data, and cagrilintide is the most advanced amylin analogue. If an amylin analogue added to semaglutide, the question is what it adds to a triple agonist. That is an open research question, and it is exactly the kind of question research peptides exist to investigate.

Side effect profile in the literature

Cagrilintide’s trial data shows the gastrointestinal effects familiar from the incretin class: nausea, constipation and reduced appetite, mostly mild to moderate and mostly early. Injection site reactions appeared more often than with semaglutide. In REDEFINE 1, the combination did not produce substantially more gastrointestinal effects than semaglutide alone, which was one of the trial’s more encouraging findings. As with retatrutide, the long term safety picture will only become clear with more Phase 3 data.

The Reta Bangkok retatrutide and cagrilintide blend

Our retatrutide and cagrilintide blend contains 5 mg of retatrutide and 5 mg of cagrilintide in a single lyophilised vial. One vial, one reconstitution, both compounds in a fixed ratio. For researchers studying the incretin and amylin pathways together, a fixed blend removes the variable of reconstituting and combining two separate vials, and it is considerably cheaper than buying both compounds individually.

Reconstitution follows the same steps as any of our peptides: bacteriostatic water added slowly down the glass, a gentle swirl, then refrigeration at 2 to 8 °C. Our reconstitution guide covers the process in full, and the reconstitution calculator gives the concentration for any water volume.

Buying cagrilintide in Thailand

Cagrilintide is not an approved medicine anywhere, so it is not available through pharmacies in Thailand or anywhere else. It exists only as a research compound. At the time of writing, Reta Bangkok is the only Thai supplier we know of that stocks it, and we stock it in the blend described above. An independent lab tests every batch, and the certificate of analysis sits on the product page. Orders placed before 3 pm go out the same day in Bangkok, and we ship nationwide across Thailand. If you need cagrilintide as a standalone vial rather than in the blend, contact us on WhatsApp and we will tell you what we can arrange.

References

1. Lau DCW et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398:2160-2172.
2. Garvey WT et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). N Engl J Med. 2025.
3. Kruse T et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem. 2021;64:11183-11194.
4. Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, a Phase 2 Trial. N Engl J Med. 2023;389:514-526.

All products on Reta Bangkok are for laboratory research use only, not for human or veterinary use.